Sesterterpene compound and extract l01 of leucosceptrum canum, and use thereof in treatment of psoriasis

By extracting and isolating disequiterpene compounds and extract L01 from Rice Tuanhua, the toxic side effects and dissatisfaction of existing psoriasis treatment drugs are solved, and effective anti-inflammatory and Immunosuppressive effects provide new immunosuppressive agent strategies.

WO2024235195A1PCT designated stage expired Publication Date: 2024-11-21KUNMING INST OF BOTANY CHINESE ACAD OF SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092859
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing psoriasis treatment drugs have problems such as toxic side effects, dissatisfaction with efficacy and expensive prices, and lack effective immunosuppressants, especially in the treatment of autoimmune diseases.

Method used

Disequiterpene compounds and extract L01 were extracted and isolated from rice dumplings, and the compound was obtained by organic solvent extraction, reduced pressure distillation, column chromatography and high performance liquid chromatography, and used to prepare anti-inflammatory and immunization Inhibiting drugs, used to treat psoriasis.

Benefits of technology

In vitro and in vivo experiments, the secretion of inflammatory cytokine IFN-γ is significantly reduced, the clinical onset symptoms of psoriatic mice are improved, and the skin pathological damage and systemic immune response are alleviated, providing safe and efficient immunosuppressant candidate materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092859_21112024_PF_FP_ABST
    Figure CN2024092859_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided in the present application are a sesterterpene compound and an extract L01 of Leucosceptrum canum, and the use thereof in the treatment of psoriasis, which belongs to the technical field of natural medicinal chemistry. The sesterterpene compound of Leucosceptrum canum provided in the present invention has any one of the structures as represented by 9-12, has a very rare skeleton type, has anti-inflammatory and immunosuppressive activities, and can be used in the preparation of anti-inflammatory drugs and immunosuppressive drugs. Further provided in the present invention are an extract L01 of Leucosceptrum canum having compounds 1-12 as characteristic components, and the use thereof in the preparation of anti-inflammatory drugs and immunosuppressive drugs. The experiment result shows that the sesterterpene compound of Leucosceptrum canum provided in the present invention has significant inhibitory effect on the secretion of pro-inflammatory cytokine IFN-γ in mouse T cells stimulated by CD3 / CD28 monoclonal antibody. The compound 6 and the extract L01 of Leucosceptrum canum obtained by means of the technical solutions of the present application can significantly improve the clinical symptoms of psoriasis in the in vivo experiments.
Need to check novelty before this filing date? Find Prior Art

Description

Diterpenoid compounds and extract L01 from the Flos Oryzias and their application in the treatment of psoriasis

[0001] This application claims priority to the Chinese invention patent application filed with the China Patent Office on May 17, 2023, with application number 202310552734.X and application name “Diquat Diterpenoid Compounds and Extracts L01 of Rice Flos and Their Application in Pharmaceutical Manufacturing”, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present application belongs to the technical field of natural medicinal chemistry, and specifically relates to a Vulgaris sesquiterpenoid compound and extract L01 and their application in the treatment of psoriasis. Background Art

[0003] Autoimmune diseases are a class of diseases caused by the body's immune system producing local or systemic abnormal immune responses to self-antigens, leading to tissue damage. These diseases include psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis. Currently, there are over 80 reported autoimmune diseases, with diverse clinical manifestations and an increasing incidence, which pose a serious threat to human health.

[0004] Psoriasis, also known as "psoriasis," is a chronic autoimmune disease with a global prevalence of 2-3%. Psoriasis is categorized into plaque psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis, with plaque psoriasis being the most common. Clinical manifestations include erythema and scaling, and can occur throughout the body. Psoriasis patients often develop complications such as psoriatic arthritis, lymphoma, cardiovascular disease, hypertension, diabetes, and depression. Currently, immunosuppressive drugs are the primary treatment for autoimmune diseases. Although a variety of effective immunosuppressive drugs are available for clinical use, they still face numerous challenges, including significant side effects, unsatisfactory efficacy, and high costs. The development of new immunosuppressive drugs is urgently needed.

[0005] Natural products play an important role in the treatment of autoimmune diseases due to their unique mechanisms of action and minimal toxicity and side effects. Many natural products derived from traditional Chinese medicines have significant anti-inflammatory and immunosuppressive effects. Plant terpenoids, in particular, have shown remarkable anti-inflammatory and immunosuppressive activity, making them an important source for the discovery of new natural anti-inflammatory and immunosuppressive drugs.

[0006] Leucosceptrum canum is a perennial shrub or small tree belonging to the genus Leucosceptrum in the family Lamiaceae. Its leaves and bark have high medicinal value and are used by the Yunnan people for muscle relaxation, hemostasis, and anti-inflammatory treatments, including fever, stomachache, traumatic bleeding, closed fractures, and impetigo. While some diterpenoids have been identified from Leucosceptrum canum, their anti-inflammatory and immunosuppressive activities have not been reported.

[0007] Summary of the Invention

[0008] In view of this, the purpose of this application is to provide the dipterpene compounds and extract L01 of the Flos Oryzias and their application in the treatment of psoriasis.

[0009] In order to achieve the above-mentioned purpose of this application, this application provides the following technical solutions:

[0010] A diterpenoid compound represented by any one of the following structural formulas 9 to 12,

[0011] The present application provides a method for preparing the diterpenoid compounds 9 to 12 described in the above scheme, comprising the following steps:

[0012] (1) extracting the rice flower with an organic solvent to obtain an extract;

[0013] (2) subjecting the extract to vacuum distillation and concentrating to obtain an extract;

[0014] (3) dissolving the extract and performing column chromatography separation and high performance liquid chromatography separation in sequence to obtain the diterpenoid compound.

[0015] The column chromatography separation includes silica gel column chromatography, MCI column chromatography or reverse phase C18 column chromatography, and dextran gel column chromatography performed in sequence; the high performance liquid chromatography separation adopts preparative or semi-preparative high performance liquid chromatography.

[0016] The present application uses an organic solvent to extract the rice flower to obtain an extract. Before extraction, the present application preferably crushes the rice flower to 30 mesh. In the present application, the rice flower can be taken from the above-ground part or any tissue of the rice flower, such as the leaves, flowers or stems of the rice flower and dried in the shade; the present application has no special requirements for the moisture content of the rice flower, and fresh or dried rice flowers can be used.

[0017] In the present application, the organic solvent preferably includes one or more of methanol, ethanol, acetone, chloroform, dichloromethane and petroleum ether; the amount of the organic solvent added to each kilogram of dry weight of the rice ball flower is preferably 5L. In the present application, the extraction is preferably cold soaking extraction or hot reflux extraction. In the present application, the temperature of the cold soaking extraction is preferably room temperature, and the

[0018] The number of cold soaking extractions is preferably 2 to 5 times, more preferably 3 to 4 times; the duration of each extraction is preferably 24 to 48 hours, more preferably 36 to 48 hours; after each cold soaking extraction, the resulting extraction system is filtered, and the filtrates after each filtration are combined. In the present application, the temperature of the hot reflux extraction is preferably 40 to 50°C, more preferably 45 to 50°C; the duration of the hot reflux extraction is preferably 4 to 6 hours, more preferably 4 to 5 hours.

[0019] After obtaining the extract, the present application subjects the extract to vacuum distillation and concentration to obtain an extract. In the present application, the vacuum distillation temperature is preferably 35-45°C, the duration is preferably 60-100 minutes, and the concentration factor of the vacuum distillation is preferably 50-fold. After vacuum distillation, the organic solvent in the extract is removed, and the extract is simultaneously concentrated.

[0020] After obtaining the extract, the present application dissolves the extract and sequentially performs column chromatography separation and high performance liquid chromatography separation to obtain the diterpenoid compound. In the present application, the organic solvent used to dissolve the extract is preferably chloroform, and the organic solvent used to dissolve the extract is 1.5 to 3 times the mass of the extract. In the present application, the column chromatography separation preferably includes silica gel column chromatography, MCI column chromatography or reverse phase C 18 Column chromatography, dextran gel column chromatography. In the present application, the column filling process of the silica gel column chromatography is preferably: packing the column with 200-300 mesh silica gel; after dissolving the extract, mix it with 1-1.5 times (mass multiple) of 200-300 mesh silica gel, and the mixed sample is dried and finely ground and sieved before being transferred to a silica gel column for column chromatography. In the present application, the silica gel column chromatography preferably adopts gradient elution, and the mobile phase used in the gradient elution is preferably a mixed solvent composed of solvent A and solvent B in a volume ratio of 1:0 to 0:1; the solvent A is preferably any one of dichloromethane, chloroform and petroleum ether, and the solvent B is preferably any one of dichloromethane, chloroform, acetone, ethyl acetate and methanol. The present application preferably performs reduced pressure concentration and thin layer chromatography detection on the fractions obtained by the gradient elution, and then combines the same fractions. In the present application, the specific elution procedure of the silica gel column chromatography is preferably: gradient elution with PE:CH2Cl2 (1:0, 1:1, 0:1, v / v) and CH2Cl2:Me2CO (9:1, 4:1, 1:1), and the obtained fractions are combined after thin layer chromatography detection to obtain a total of 6 fractions to be separated, namely Fr.1 (PE), Fr.2 (PE:CH2Cl2=1:1), Fr.3 (CH2Cl2), Fr.4 (CH2Cl2:Me2CO=9:1), Fr.5 (CH2Cl2:Me2CO=4:1), and Fr.6 (CH2Cl2:Me2CO=1:1).

[0021] Fr.4 was subjected to MCI column chromatography or reverse phase C 18 After column chromatography, the present application subjected the obtained fraction Fr.4-2 to dextran gel column chromatography. In a specific embodiment of the present application, the dextran gel model is LH-20. In the present application, the mobile phase used in the dextran gel column chromatography is preferably a mixed solvent consisting of dichloromethane and methanol in a volume ratio of 1:1. After the dextran gel column chromatography, four subfractions were obtained: Fr.4-2-1, Fr.4-2-2, Fr.4-2-3, and Fr.4-2-4.

[0022] After the above column chromatography, the obtained fractions Fr.4-2-1, Fr.4-2-2, Fr.4-2-3, and Fr.4-2-4 are separated by high performance liquid chromatography to obtain the diterpenoid compound. In the present application, the high performance liquid chromatography separation adopts preparative or semi-preparative high performance liquid chromatography; the chromatographic conditions of the high performance liquid chromatography are preferably: C 18 The chromatographic column is a C8 chromatographic column, a phenyl chromatographic column or a silica gel chromatographic column, and the column temperature is 35°C; a gradient elution is adopted, and the mobile phase is a mixed solvent composed of acetonitrile and water in a volume ratio of 100:0 to 5:95; the flow rate is 3 mL / min. In the specific embodiment of the present application, the separation procedure of the high performance liquid chromatography is preferably: using an Agilent 1200 semi-preparative liquid chromatograph, a ZorbaxSB-C 18 column (5 μm, 9.4×250 mm, 3 mL / min), column temperature 35°C; elution conditions in MeCN-H2O (75:25, v / v)

[0023] Compound 3 (t R 14.5min), compound 4 (t R 17.2min), compound 6 (t R 21.4min); Compound 1 (t R 11.6min), compound 8 (t R 13.5min), compound 10 (t R 14.8min); Compound 7 (t R 9.7min), compound 9 (t R 10.5min)、12(t R 13.8min); 11 (t R11.5min), compound 2 (t R 14.4min), compound 5 (t R 28.6min).

[0024] This application provides the above-mentioned celery extract L01 and its preparation method, which comprises the following steps:

[0025] (1) mixing the crushed rice flower with an organic solvent, performing ultrasonic treatment, and collecting the extract; the organic solvent comprises one or more of methanol, ethanol, acetone, chloroform, dichloromethane, and petroleum ether; the material-liquid ratio of the crushed rice flower aerial part to the organic solvent is 1:(3-8); and the ultrasonic treatment time is 10-40 min;

[0026] (2) concentrating the extract to obtain a crude extract by rotary evaporation at a temperature of 30 to 60° C.

[0027] (3) The crude extract was separated and eluted by silica gel column chromatography, and the acetone elution phase was collected and concentrated to obtain the rice flower extract L01: the eluents used in the silica gel column chromatography elution process were petroleum ether and acetone, respectively; the concentration treatment was achieved by rotary evaporation at a temperature of 30 to 60°C.

[0028] Specifically, the preparation method of the rice ball extract L01 is:

[0029] (1) The aboveground parts of the rice flower were dried in the shade and crushed into 30 mesh, mixed thoroughly with 10 L of petroleum ether at room temperature, and ultrasonically extracted three times for 30 min each time. The extracts were filtered and combined;

[0030] (2) The extract was concentrated by a rotary evaporator at 45° C. to obtain an extract;

[0031] (3) The extract was dissolved in 0.5 L of chloroform, mixed with silica gel 200-300 mesh, allowed to dry, ground and sieved, and subjected to column chromatography using silica gel 200-300 mesh. The extract was eluted with petroleum ether and acetone in sequence, and the acetone eluate was concentrated to obtain the rice flower extract L01.

[0032] The present application also provides the use of diperquiterpenoid compounds 1 to 12 and extract L01 in the preparation of anti-inflammatory drugs or immunosuppressive drugs, as well as their use in the preparation of T cell proliferation inhibitors or cytokine inhibitors and anti-psoriasis drugs.

[0033] In addition, the present application also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more of the diterpenoid compounds 1 to 12.

[0034] And, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the Oryza sativa extract L01.

[0035] In the present application, the mass percentage of compounds 1 to 12 or extract L01 in the pharmaceutical composition is preferably 0.1 to 99%, more preferably 0.5 to 90%; the total mass percentage of the pharmaceutical carrier in the pharmaceutical composition is preferably 1 to 99.9%, more preferably 10 to 99.5%.

[0036] The present application does not specifically limit the pharmaceutical carrier; any pharmaceutical carrier known in the art may be used, such as one or more of a solid, semisolid, or liquid diluent, a filler, or a pharmaceutical product adjuvant. In the present application, the pharmaceutical composition preferably includes liquid preparations, solid preparations, sprays, or mists; the liquid preparations preferably include injections, suspensions, emulsions, solutions, or syrups; and the solid preparations preferably include tablets, capsules, granules, or granules.

[0037] There is no particular limitation on the preparation method of the pharmaceutical composition in the present application, and any preparation method well known in the art may be used.

[0038] In the present application, the administration of the pharmaceutical composition and extract L01 is preferably by injection, oral administration, sublingual administration or mucosal dialysis; the injection preferably includes intravenous injection, intravenous drip, intramuscular injection, intraperitoneal injection or subcutaneous injection.

[0039] In the present application, the pharmaceutical composition and extract L01 are preferably used in the form of a dosage per unit body weight. In the present application, the dosage per unit body weight is preferably 0.5 to 500 mg / kg.

[0040] By adopting the above technical solution, this application has the following beneficial effects:

[0041] The diperquiterpenoid compounds 1 to 12 obtained by the technical solution of the present application significantly reduced the secretion of the inflammatory cytokine IFN-γ in mouse T cells stimulated by CD3 / CD28 monoclonal antibodies in in vitro experiments.

[0042] In in vivo experiments with mice, both compound 6 and the rice flower extract L01 significantly reduced the levels of pro-inflammatory cytokines IFN-γ and IL-17A in the serum of psoriasis mice, significantly improved clinical symptoms of psoriasis, such as weight loss, back skin scaling and thickness, and alleviated pathological skin damage and systemic immune responses. This provides candidate materials for screening safe and effective immunosuppressants and offers an effective strategy for the treatment of autoimmune diseases such as psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] FIG1 is a single crystal X-ray diffraction structure diagram of the diterpenoid compound 1 of the present application;

[0044] FIG2 is a single crystal X-ray diffraction structure diagram of the diterpenoid compound 2 of the present application;

[0045] FIG3 is a single crystal X-ray diffraction structure diagram of the diterpenoid compound 4 of the present application;

[0046] Figure 4 is a schematic structural diagram of the diterpenoid compounds 1 to 12 of the present application;

[0047] FIG5 is a picture of the back skin of mice in each group after being treated with the oryzae oryzae extract L01 of the present application;

[0048] FIG6 is an H&E stained section of the back skin of mice after treatment with the oryzae oryzae extract L01 of the present application;

[0049] FIG7 is a graph showing changes in the levels of cytokines IFN-γ and IL-17A in the serum of mice after treatment with the Glomus oryzae extract L01 of the present application;

[0050] FIG8 is a picture of the back skin of mice in each group after treatment with the diterpenoid compound 6 of the present application;

[0051] FIG9 is an H&E stained section of the back skin of mice after treatment with the dipyridone compound 6 of the present application;

[0052] FIG10 is a graph showing changes in the levels of cytokines IFN-γ and IL-17A in mouse serum after treatment with the diperquiterpenoid compound 6 of the present application. DETAILED DESCRIPTION

[0053] Below, in conjunction with the accompanying drawings, the examples of the present application are used to further illustrate the dipernet compounds and extract L01 of the Flos Oryzias and their application in the treatment of psoriasis, but they should not be understood as limiting the scope of protection of the present application.

[0054] Example 1

[0055] Specifically, the extraction and separation steps of the diterpenoid compounds 1 to 12 in this application are as follows:

[0056] (1) The aboveground parts of the rice flower collected from Yunnan were dried in the shade and crushed to 30 mesh to obtain 10.0 kg of sample. The sample was then soaked and extracted with 50 L of petroleum ether at room temperature for 3 times, each time for 48 h. The extracts were filtered and combined, and the solvent was removed by vacuum distillation to obtain 230 g of total extract.

[0057] (2) The extract was dissolved in 2 L of chloroform, mixed with 253 g of silica gel (200-300 mesh), placed to dry, ground and sieved, and loaded with 2.0 kg of silica gel (200-300 mesh) for column chromatography. Gradient elution was performed with petroleum ether: dichloromethane (1:0, 1:1, 0:1, v / v) and chloroform: acetone (9:1, 4:1, 1:1) in sequence. The obtained fractions were concentrated under reduced pressure and detected by thin layer chromatography. After combining the same fractions, a total of 6 fractions to be separated were obtained, namely Fr.1 (petroleum ether), Fr.2 (petroleum ether: chloroform = 1:1), Fr.3 (chloroform), Fr.4 (chloroform: acetone = 9:1), Fr.5 (chloroform: acetone = 4:1), and Fr.6 (chloroform: acetone = 1:1);

[0058] (3) Fr.4 (48 g) was subjected to MCI column chromatography with a gradient elution of methanol:water (50%, 60%, 70%, 80%, 90%, 100%, v / v) to obtain four subfractions Fr.4-1 to Fr.4-4;

[0059] Fraction Fr.4-2 was subjected to Sephadex column chromatography and eluted with dichloromethane:methanol (1:1, v / v) to obtain four subfractions Fr.4-2-1 to Fr.4-2-4;

[0060] The fractions Fr.4-2-1 to Fr.4-2-4 were separated by high performance liquid chromatography using an Agilent 1200 semi-preparative liquid chromatograph, ZorbaxSB-C 18 column (5 μm, 9.4×250 mm, 3 mL / min), column temperature 35°C; under the elution condition of MeCN-H2O (75:25, v / v), compound 3 (t R 14.5min), compound 4 (t R 17.2min), compound 6 (t R 21.4min); Compound 1 (t R 11.6min), compound 8 (t R 13.5min), compound 10 (t R 14.8 min); elution in MeCN-H2O (80:20, v / v)

[0061] Compound 7 (t R 9.7min), compound 9 (t R 10.5min)、12(t R13.8min); under the elution condition of MeCN-H2O (60:40, v / v), compounds 11 (tR11.5min), 2 (t R 14.4min), compound 5 (t R 28.6min);

[0062] The obtained masses of each compound were compound 1 (2.0 mg), compound 2 (3.2 mg), compound 3 (9.5 mg), compound 4 (3.5 mg), compound 5 (2.0 mg), compound 6 (35.0 mg), compound 7 (2.0 mg), compound 8 (4.0 mg), compound 9 (3.5 mg), compound 10 (13.0 mg), compound 11 (1.2 mg), and compound 12 (2.5 mg).

[0063] Physical and spectral data of compounds 1-12:

[0064] Compound 1: white solid; specific rotation +12.0 (c 0.30, MeOH); IR (KBr) ν max 3429, 2955, 2931, 2870, 1742, 1721, 1640, 1377, 1164cm -1 ; High resolution mass spectrometry HRESIMS m / z 431.2443 [MH] - ; 1 H and 13 The CNMR data are shown in Table 1.

[0065] Compound 2: white solid; specific rotation +34.9 (c 0.10, MeOH); IR (KBr) ν max 3435, 2973, 2936, 2871, 1760, 1716, 1452, 1378, 1140cm -1 ; High resolution mass spectrometry HRESIMS m / z455.2405[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 1.

[0066] Compound 3: colorless oily liquid; specific rotation +61.7 (c 0.10, MeOH); IR (KBr) ν max 3437, 2973, 2936, 2871, 1715, 1452, 1377, 1138, 1013cm -1; High resolution mass spectrometry HRESIMS m / z 439.2459 [M+Na] + ; 1 H and 13 The CNMR data are shown in Table 1.

[0067] Compound 4: colorless oily liquid; specific rotation +61.5 (c 0.13, MeOH); IR (KBr) ν max 3470, 2967, 2938, 2874, 1684, 1462, 1394, 1378, 1010cm -1 ; High resolution mass spectrometry HRESIMS m / z 375.2141[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 1.

[0068] Compound 5: colorless oily liquid; specific rotation +39.0 (c 0.06, MeOH); IR (KBr) ν max 3438, 2971, 2939, 2871, 1704, 1684, 1452, 1379, 1055cm -1 ; High resolution mass spectrometry HRESIMS m / z 391.2091[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 2.

[0069] Compound 6: white solid; specific rotation +38.0 (c 0.10, MeOH); IR (KBr) ν max 3429, 2956, 2874, 1766, 1661, 1457, 1380, 1166cm -1 ; High resolution mass spectrometry HRESIMS m / z 455.2396[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 2.

[0070] Compound 7: colorless oily liquid; specific rotation +60.8 (c 0.05, MeOH); IR (KBr) ν max 3435, 2937, 2870, 1712, 1674, 1451, 1378, 1144cm -1 ; High resolution mass spectrometry HRESIMS m / z 469.2195[M+Na] + ;1 H and 13 The CNMR data are shown in Table 2.

[0071] Compound 8: colorless oily liquid; specific rotation +60.7 (c 0.06, MeOH); IR (KBr) ν max 3436, 2970, 2871, 1715, 1687, 1452, 1379, 1170cm -1 ; High resolution mass spectrometry HRESIMS m / z 471.2353[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 2.

[0072] Compound 9: colorless oily liquid; specific rotation +29.3( c 0.10, MeOH); infrared IR (KBr)ν max 2969, 2939, 2871, 1770, 1685, 1451, 1380, 1168cm -1 ; High resolution mass spectrometry HRESIMS m / z 501.2458[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 3.

[0073] Compound 10: colorless oily liquid; specific rotation +60.7 (c 0.06, MeOH); IR (KBr) ν max 3451, 2969, 2939, 2871, 1683, 1449, 1380, 1371 cm-1; High resolution mass spectrometry (HRESIMS) m / z 517.2775 [M+Na] + ; 1H and 13 The CNMR data are shown in Table 3.

[0074] Compound 11: Colorless oily liquid; specific rotation +32.0 (c 0.11, MeOH); IR (KBr) ν max 3446, 2960, 2833, 1730, 1690, 1422, 1381, 1200cm -1 ; High resolution mass spectrometry HRESIMS m / z 471.2353[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 3.

[0075] Compound 12: Colorless oily liquid; specific rotation +45.5 (c 0.06, MeOH); IR (KBr) ν max 3433, 2966, 2835, 1718, 1688, 1441, 1377, 1175cm -1 ; High resolution mass spectrometry HRESIMS m / z 471.2353[M+Na] + ; 1 H and 13 The CNMR data are shown in Table 3.

[0076] Figures 1 to 3 are the single crystal X-ray diffraction structures of compound 1, compound 2, and compound 4, respectively.

[0077] From the physical and spectral data of compounds 1 to 12, it can be seen that compounds 1 to 12 conform to the structures shown in Figure 4.

[0078] Table 1 Compounds 1 to 4 1 H and 13 CNMR data (acetone-d6, Jin Hz)

[0079] Table 2 Compounds 5 to 8 1 H and 13 C NMR data (acetone-d6, Jin Hz)

[0080] Table 3 Compounds 9 to 12 1 H and 13 C NMR data (acetone-d6, J in Hz)

[0081] Example 2

[0082] Specifically, the preparation of the rice ball extract L01 in this application:

[0083] (1) The aboveground part of the rice ball flower collected from Yunnan was dried in the shade and crushed to 30 mesh to obtain 2.0 kg of sample.

[0084] 10L petroleum ether was thoroughly mixed, ultrasonic extraction was performed three times, each time for 30 min, and the extracts were combined after filtration;

[0085] (2) The extract was concentrated by rotary evaporation at 45°C to obtain 30 g of extract;

[0086] (3) The above extract was dissolved in 0.5 L of chloroform, mixed with 33 g of silica gel (200-300 mesh), left to dry, ground and sieved, and loaded with 240 g of silica gel (200-300 mesh) for column chromatography. The extract was eluted with 100% petroleum ether and 100% acetone in sequence. The acetone eluate was concentrated to obtain the rice flower extract L01 (18 g).

[0087] Example 3

[0088] Compounds 1 to 12 of the present application were tested for in vitro immunosuppressive activity:

[0089] CD3, CD28 monoclonal antibodies, and IFN-γ detection kits were purchased from BD Bioscience, CCK-8 kits were purchased from Meilun, and RPMI-1640 culture medium and fetal bovine serum were purchased from Biological Industries.

[0090] Preparation of test samples: The 12 compounds of Example 1 were dissolved in DMSO to prepare 20 mM stock solutions.

[0091] Specific methods: Splenocytes were aseptically isolated from 6-8 week old female C57BL / 6 mice, and T cells were isolated using the nylon wool column method. T cells (4×105 / well) were then inoculated into 96-well plates (coated with 5μg / mL LCD3 monoclonal antibody). At the same time, each group was added with 40, 20, 10, 5, 2.5, and 1.25μM of the prepared compound and 2μg / mL LCD28 monoclonal antibody, respectively. The cells were cultured in a 37°C / 5% CO2 incubator. After 48 hours, the cell supernatant was collected and IFN-γ secretion in the supernatant was detected by enzyme-linked immunosorbent assay (ELISA). 10μL of CCK-8 reagent was added to each well of cells, and the OD was measured after incubation at 37°C for 4 hours. 450 To evaluate cell proliferation, a cyclosporine (CsA) positive control group, a DMSO negative control group, an unstimulated group, and a blank control group were also set up. The inhibitory activity of the compounds against IFN-γ was calculated, and the half-maximal inhibitory concentration (IC50) was analyzed using GraphPad Prism software. The results are shown in Table 3.

[0092] Table 3 Compounds 1 to 12 inhibit the secretion of proinflammatory cytokine IFN-γ in mouse T cells stimulated by CD3 / CD28 monoclonal antibody a CsA: cyclosporine A (CsA), positive control.

[0093] As shown in Table 3, compounds 1-12 of the present application significantly inhibited the secretion of the pro-inflammatory cytokine IFN-γ in mouse T cells stimulated by CD3 / CD28 monoclonal antibodies, indicating that these compounds have anti-inflammatory and immunosuppressive effects. Furthermore, a certain structure-activity relationship between these compounds and their activity is established, providing a basis for future compound structure optimization and modification.

[0094] Example 4

[0095] In vivo anti-psoriasis activity test of the extract L01 from Oryza sativa L.

[0096] BABL / 6 mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., imiquimod cream was purchased from Sichuan Mingxin Pharmaceutical Co., Ltd., and vaseline was purchased from Tianjin Zhiyuan Chemical Reagent Co., Ltd.

[0097] Establishment of an Imiquimod-Induced Psoriasis Mouse Model and Pharmacodynamic Study: Mice were randomly divided into a normal group, a model group, a methotrexate (MTX)-treated group (1 mg / kg), and a terpenoid-treated group (50, 150, and 450 mg / kg), with six mice per group. The backs of the mice were hairless before the experiment. Starting on day 1, 62.5 mg of 0.5% imiquimod ointment was evenly applied to the backs of the mice in the normal control group. The same amount of petrolatum was applied to the backs of the mice in the normal control group once daily for 6 days. Each treatment group received the drug by oral gavage from day 1 to day 6. During the experiment, mice were weighed and scored using the Psoriasis Area and Severity Index (PASI) according to the following criteria: 0 (no erythema or scaling, normal skin); 1 (mild erythema with a few fine scales, with the lesions slightly elevated above normal skin); 2 (moderate erythema with scales covering the lesions, with flaky or moderately raised lesions); 3 (severe dark erythema covering almost all lesions, with thick scales or prominent lesions); and 4 (very severe and very dark erythema with all lesions covered by thick, lamellar scales, and very pronounced thickening and protrusions). After the experiment, dorsal skin samples were collected for pathological sections. Serum levels of the proinflammatory cytokines IFN-γ and IL-17A were measured by ELISA.

[0098] As can be seen from Figure 5, the rice flower extract L01 significantly improved the symptoms of psoriasis in mice. The experimental results in Figure 6 show that the rice flower extract L01 significantly inhibited the pathological damage of the skin tissue of psoriasis mice. HE staining of skin pathological sections found that the epidermis of the skin of psoriasis mice was thickened, the stratum corneum showed incomplete keratinization and epidermal protrusions, the dermis was thickened and lymphocyte infiltration occurred, and the above symptoms of the mice in the treatment group were significantly improved. The experimental results in Figure 7 show that the rice flower extract L01 significantly reduced the levels of pro-inflammatory cytokines IFN-γ and IL-17A in the serum of psoriasis mice. These studies confirm that the rice flower extract L01 has a good anti-psoriasis effect in vivo and has good application prospects in the clinical treatment of autoimmune diseases such as psoriasis.

[0099] Example 5

[0100] The diterpenoid compound 6 of the present application was tested for its in vivo anti-psoriasis activity:

[0101] The method for establishing an imiquimod-induced psoriasis mouse model was the same as in Example 5. Mice were randomly divided into a normal group, a model group, a methotrexate (MTX) treatment group (1 mg / kg), and a compound 6 treatment group (25 and 50 mg / kg), with 6 mice in each group. From day 1 to day 6, each treatment group was administered by intraperitoneal injection. During the experiment, the mice were weighed and PASI scores were performed. After the experiment, the back skin of the mice was taken and pathological sections were made. The levels of proinflammatory cytokines IFN-γ and IL-17A in the mouse serum were detected by ELISA.

[0102] The experimental results in Figure 8 show that compound 6 significantly improved the symptoms of psoriasis in mice. Figure 9 shows that compound 6 significantly inhibited the pathological damage of the skin tissue of psoriasis mice. HE staining of skin pathological sections found that the epidermis of the skin of psoriasis mice was thickened, the stratum corneum showed incomplete keratinization and epidermal protrusions, the dermis was thickened and lymphocyte infiltration occurred, and the above symptoms of the mice in the treatment group were significantly improved. The experimental results in Figure 7 showed that compound 6 significantly reduced the levels of proinflammatory cytokines IFN-γ and IL-17A in the serum of psoriasis mice. These structures indicate that compound 6 has a good anti-psoriatic effect in vivo and can be used to treat autoimmune diseases such as psoriasis.

[0103] Formulation Examples

[0104] In the following formulation examples, conventional reagents are selected and the formulations are prepared according to conventional methods. This application example only demonstrates that at least one of the Oryza sativa extract L01 or compounds 1 to 12 described in this application can be prepared into different formulations, and does not specifically limit the specific reagents and operations.

[0105] (1) The extract L01 or compounds 1 to 12 of the present application is prepared into tablets:

[0106] Tablet ingredients: 10 mg of Oryza sativa extract L01 or one of compounds 1 to 12, or a mixture of any of them, 180 mg of lactose, 55 mg of starch, and 5 mg of magnesium stearate;

[0107] Preparation method: Mix the raw materials, lactose and starch, evenly moisten with propylene glycol, sieve the moistened mixture and dry it, sieve it again, add magnesium stearate, and then compress the mixture into tablets. Each tablet weighs 250 mg and contains 10 mg of the raw materials.

[0108] (2) The extract L01 or compounds 1 to 12 of the present application is prepared into capsules:

[0109] Capsule ingredients: 10 mg of Oryza sativa extract L01 or one of compounds 1 to 12, or a mixture of any of them, 187 mg of lactose, and 3 mg of magnesium stearate;

[0110] Preparation method: Mix the raw materials and auxiliary agents, sieve, mix evenly, and put the resulting mixture into hard gelatin capsules. Each capsule weighs 200 mg and contains 10 mg of the raw materials.

[0111] (3) Dissolve the extract L01 of Oryza sativa L. or any one of compounds 1 to 12 in sterile water for injection, stir until the raw materials are dissolved, filter through a sterile suction funnel and sterile fine filtration, and then pack into ampoules, freeze-dry at low temperature, and aseptically seal to obtain a drug powder injection.

[0112] (4) After dissolving the extract L01 of Oryza sativa or one or more of compounds 1 to 12 in DMSO, adding water for injection according to conventional methods, fine filtering, filling and sterilization are prepared into an injection solution, wherein the concentration of the injection solution is 0.5 to 5 mg / mL.

[0113] (5) Prepare an oral solution by using the rice flower extract L01 or one or more of compounds 1 to 12 according to a conventional oral solution preparation method.

[0114] The above is only a preferred embodiment of the present application. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present application. These improvements and modifications should also be regarded as the scope of protection of the present application.

Claims

1. A diterpenoid compound represented by any one of the following structural formulas 9 to 12, 2. The method for preparing the diterpenoid compounds 9 to 12 according to claim 1, characterized in that: The following steps are involved: (1) extracting rice flower with an organic solvent to obtain an extract; the organic solvent includes one or more of methanol, ethanol, acetone, chloroform, dichloromethane and petroleum ether; the extraction is cold soaking extraction or hot reflux extraction; the temperature of the cold soaking extraction is room temperature, the number of cold soaking extractions is 2 to 5 times, and the time of each extraction is 24 to 48 hours; the temperature of the hot reflux extraction is 40 to 50° C., and the extraction time is 4 to 6 hours; (2) subjecting the extract to vacuum distillation to concentrate to obtain an extract; the vacuum distillation temperature is 30 to 60° C.; (3) dissolving the extract and performing column chromatography separation and high performance liquid chromatography separation in sequence to obtain the diterpenoid compound; the column chromatography separation comprises silica gel column chromatography, MCI column chromatography or reverse phase C 18 Column chromatography, dextran gel column chromatography; the high performance liquid chromatography separation adopts preparative or semi-preparative high performance liquid chromatography; The silica gel filler of the silica gel column chromatography is 200-300 mesh; the silica gel column chromatography adopts a first gradient elution, and the mobile phase adopted by the first gradient elution is a mixed solvent composed of solvent A and solvent B in a volume ratio of 1:0-0:1; the solvent A is any one of dichloromethane, chloroform and petroleum ether, and the solvent B is any one of dichloromethane, chloroform, acetone, ethyl acetate and methanol; The MCI column chromatography or reverse phase C 18 The column chromatography adopts a second gradient elution, wherein the mobile phase adopted in the second gradient elution is a mixed solvent consisting of methanol and water in a volume ratio of 50% to 100%; The mobile phase used in the dextran gel column chromatography is a mixed solvent consisting of dichloromethane or chloroform and methanol in a volume ratio of 1:1; The chromatographic conditions of the high performance liquid chromatography are: 18 The chromatographic column is a C8 chromatographic column, a phenyl chromatographic column or a silica gel chromatographic column, and the column temperature is 20-50°C; gradient elution is adopted, and the mobile phase is a mixed solvent composed of acetonitrile: water or methanol: water in a volume ratio of 100:0-5:95; the flow rate is 1-3 mL / min.

3. The preparation method according to claim 2, characterized in that: The rice flower is taken from the above-ground part or any tissue of the rice flower.

4. The preparation method according to claim 3, characterized in that: The rice ball flower is the shade-dried leaves, flowers or stems of the rice ball flower.

5. The preparation method according to claim 4, characterized in that: The particle size of the rice balls is 30 meshes.

6. The preparation method according to claim 2, characterized in that: In step (1), the amount of the organic solvent added to each kilogram of dry weight of the rice balls is 5 L.

7. The preparation method according to claim 2, characterized in that: In step (2), the concentration multiple of the reduced pressure distillation is 50 times.

8. The preparation method according to claim 2, characterized in that: In step (3), the organic solvent for dissolving the extract is chloroform, and the amount of the organic solvent for dissolving the extract is 1.5 to 3 times the mass of the extract.

9. The preparation method according to claim 2, characterized in that: In step (3), the column packing process of the silica gel column chromatography is as follows: After the extract is dissolved, it is mixed with 1 to 1.5 times the mass of 200 to 300 mesh silica gel. The mixed sample is dried, ground, sieved, and then transferred to a silica gel column.

10. The preparation method according to claim 2, characterized in that: In step (3), the specific elution procedure of the silica gel column chromatography is: Gradient elution was performed with petroleum ether: dichloromethane volume ratio of 1:0, 1:1, 0:1 and chloroform: acetone volume ratio of 9:1, 4:1, 1:1 in sequence, and the obtained fractions were concentrated under reduced pressure and detected by thin layer chromatography, and the same fractions were combined to obtain 6 fractions to be separated, namely, petroleum ether fraction Fr.1, petroleum ether: chloroform = 1:1 fraction Fr.2, chloroform fraction Fr.3, chloroform: acetone = 9:1 fraction Fr.4, chloroform: acetone = 4:1 fraction Fr.5, and chloroform: acetone = 1:1 fraction Fr.6; The Fr.4 was subjected to MCI column chromatography or reverse phase C 18 After column chromatography, the obtained fraction Fr.4-2 After dextran gel column chromatography, four subfractions were obtained, namely, Fr.4-2-1, Fr.4-2-2, Fr.4-2-3, and Fr.4-2-4; The fractions Fr.4-2-1 to Fr.4-2-4 were separated by high performance liquid chromatography using an Agilent 1200 semi-preparative liquid chromatograph, ZorbaxSB-C 18 column: 5μm, 9.4×250mm, 3mL / min, column temperature 35℃; under the elution condition of MeCN-H2O75:25, v / v, compounds 3, 4, and 6 were obtained from Fr.4-2-1; under the elution condition of MeCN-H2O70:30, v / v, compounds 1, 8, and 10 were obtained from Fr.4-2-2; under the elution condition of MeCN-H2O80:20, v / v, compounds 7, 9, and 12 were obtained from Fr.4-2-3; under the elution condition of MeCN-H2O60:40, v / v, compounds 11, 2, and 5 were obtained from Fr.4-2-4; The structural formulas of the compounds 1 to 8 are:

11. The preparation method according to claim 10, characterized in that: The Fr.4 was subjected to MCI column chromatography, and gradient elution was performed with a methanol:water volume ratio of 50%, 60%, 70%, 80%, 90%, and 100% to obtain four subfractions Fr.4-1 to Fr.4-4.

12. The preparation method according to claim 10 or 11, characterized in that: The fraction Fr.4-2 was subjected to dextran gel column chromatography and eluted with dichloromethane:methanol in a volume ratio of 1:1 to obtain four subfractions Fr.4-2-1 to Fr.4-2-4.

13. Rice ball flower extract L01, characterized in thatIt is prepared by the following method: (1) mixing the crushed rice flower with an organic solvent, and collecting the extract after ultrasonic treatment; the organic solvent comprises one or more of methanol, ethanol, acetone, chloroform, dichloromethane and petroleum ether; the solid-liquid ratio of the crushed rice flower aerial part to the organic solvent is 1:(3-8); the ultrasonic treatment time is 10-40 min; (2) concentrating the extract to obtain a crude extract; the concentration is achieved by rotary evaporation at a temperature of 30 to 60° C.; (3) The crude extract is separated and eluted by silica gel column chromatography, and the acetone elution phase is collected and concentrated to obtain the rice flower extract L01; the eluents used in the silica gel column chromatography elution process are petroleum ether and acetone respectively; the concentration treatment is achieved by rotary evaporation at a temperature of 30 to 60°C.

14. Use of the diperpene compound according to claim 1 or the diperpene compound obtained by the preparation method according to any one of claims 2 to 12 in the preparation of anti-inflammatory drugs or immunosuppressive drugs.

15. Use of the diterpenoid compound or compound 6 according to claim 1 or the diterpenoid compounds 6, 9 to 12 obtained by the preparation method according to any one of claims 2 to 12 in the preparation of inflammatory cytokine inhibitors or anti-psoriasis drugs; The structural formula of the compound 6 is:

16. Use of the Myrica oryzae extract L01 according to claim 13 in the preparation of anti-inflammatory drugs or immunosuppressive drugs.

17. Use of the Myrica oryzae extract L01 according to claim 13 in the preparation of pro-inflammatory cytokine inhibitors or anti-psoriasis drugs.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more of the diterpenoid compounds 9 to 12 according to claim 1.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the Myrica oryzae extract L01 according to claim 13.

20. A method for preparing the extract L01 of Codonopsis pilosula, characterized in that: The steps include: (1) The above-ground parts of the rice flower were dried in the shade and crushed into 30 mesh, mixed thoroughly with 10 L of petroleum ether at room temperature, and ultrasonically extracted three times, each time for 30 min, and the extracts were filtered and combined; (2) concentrating the extract by a rotary evaporator at 45° C. to obtain an extract; (3) The extract was dissolved in chloroform, mixed with 200-300 mesh silica gel, air-dried, ground and sieved, and subjected to column chromatography using 200-300 mesh silica gel column. The extract was eluted with petroleum ether and acetone in sequence, and the acetone eluate was concentrated to obtain the rice ball extract L01.

21. The pharmaceutical composition according to claim 18 or 19, characterized in that: The pharmaceutical composition may be in the form of liquid preparations, solid preparations, sprays or aerosols.

22. The pharmaceutical composition according to claim 21, characterized in that The liquid preparations include injections, suspensions, emulsions, solutions or syrups; the solid preparations include tablets, capsules, granules or granules.

23. A tablet, characterized in that The raw materials are: 10 mg of rice ball extract L01 or one of compounds 9 to 12 or a mixture of any of them, 180 mg of lactose, 55 mg of starch, and 5 mg of magnesium stearate; The rice spherical extract L01 is the rice spherical extract L01 according to claim 13 or the rice spherical extract L01 prepared by the preparation method according to claim 20; The compounds 6, 9 to 12 are the diterpenoid compounds according to claim 1 or the diterpenoid compounds 6, 9 to 12 obtained by the preparation method according to any one of claims 2 to 12.

24. A capsule, characterized in that The raw materials are: 10 mg of rice flower extract L01 or one of compounds 9 to 12 or a mixture of any of them, 187 mg of lactose, and 3 mg of magnesium stearate; The rice spherical extract L01 is the rice spherical extract L01 according to claim 13 or the rice spherical extract L01 prepared by the preparation method according to claim 21; The compounds 6, 9 to 12 are the diterpenoid compounds according to claim 1 or the diterpenoid compounds 6, 9 to 12 obtained by the preparation method according to any one of claims 2 to 12.

Citation Information

Patent Citations

  • Dimeric sesquiterpene compound and applications thereof

    CN101787007A

  • Sesterterpene compound in rice clover, preparation method thereof and application of sesterterpene compound in pharmacy

    CN115745924A

  • Sesterterpene compound and extract L01 of Leucodendron latifolius and application of sesterterpene compound and extract L01 in pharmacy

    CN116606269A